The Application of Molecular Diagnostics to Stained Cytology Smears
- 1 May 2016
- journal article
- research article
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 18 (3) , 407-415
Abstract
No abstract availableKeywords
Funding Information
- Yeshiva University
This publication has 22 references indexed in Scilit:
- Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case reportBMC Research Notes, 2013
- Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular PathologyArchives of Pathology & Laboratory Medicine, 2013
- Molecular pathology of lung cancer: key to personalized medicineLaboratory Investigation, 2012
- BRAF Mutation Testing of Thyroid Fine-Needle Aspiration Specimens Enhances the Predictability of Malignancy in Thyroid Follicular Lesions of Undetermined SignificanceActa Cytologica, 2011
- Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to ErlotinibJournal of Thoracic Oncology, 2011
- The Application of Molecular Diagnostic Studies Interrogating EGFR and KRAS Mutations to Stained Cytologic Smears of Lung CarcinomaAmerican Journal of Clinical Pathology, 2011
- EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutationsLung Cancer, 2011
- Good Response to Gefitinib in Lung Adenocarcinoma Harboring Coexisting EML4-ALK Fusion Gene and EGFR MutationJournal of Thoracic Oncology, 2010
- Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomised trialsEuropean Journal of Cancer, 2010
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005